ENANTA PHARMACEUTICALS INC
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
ENTA$11.22-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(25,029) | $(44,934) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 7,558 | 10,354 |
| Depreciation and amortization expense | 2,439 | 2,092 |
| Non-cash interest associated with the sale of future royalties | 929 | (1,303) |
| Non-cash royalty revenue | (1,106) | (175) |
| Premium paid on marketable securities | (1,037) | — |
| Amortization of premiums on marketable securities | 322 | 1,448 |
| Loss on disposal of property and equipment | — | 6 |
| Change in operating assets and liabilities: | ||
| Accounts receivable | (927) | (146) |
| Prepaid expenses and other current assets | 1,780 | 3,556 |
| Income tax receivable | (19) | (1,837) |
| Operating lease, right-of-use assets | 1,113 | 2,656 |
| Other long-term assets | (52) | (4) |
| Accounts payable | 2,415 | 705 |
| Accrued expenses | (5,892) | (4,883) |
| Operating lease liabilities | (1,367) | 2,164 |
| Other long-term liabilities | 18 | 12 |
| Net cash used in operating activities | (18,855) | (30,289) |
| Cash flows from investing activities | ||
| Purchase of marketable securities | (190,574) | (55,016) |
| Proceeds from maturities and sale of marketable securities | 155,376 | 130,833 |
| Purchase of property and equipment | (158) | (11,283) |
| Net cash (used in) provided by investing activities | (35,356) | 64,534 |
| Cash flows from financing activities | ||
| Proceeds from October 2025 public offering, net of issuance costs of $4,802 | 69,948 | — |
| Payments on royalty sale liability, net of imputed interest | (12,895) | (11,703) |
| Payments for settlement of share-based awards | (402) | (264) |
| Proceeds from the exercise of stock options | 190 | 94 |
| Net cash provided by (used in) financing activities | 56,841 | (11,873) |
| Net increase in cash, cash equivalents and restricted cash | 2,630 | 22,372 |
| Cash, cash equivalents and restricted cash at beginning of period | 35,658 | 41,201 |
| Cash, cash equivalents and restricted cash at end of period | $38,288 | $63,573 |
| Supplemental disclosure of non-cash information: | ||
| Purchases of fixed assets included in accounts payable and accrued expenses | $— | $1,296 |
| Operating lease liabilities arising from obtaining right-of-use assets | $— | $1,101 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $5,453 | $5,480 |
| Cash received from tenant improvement allowances | $330 | $4,780 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.